期刊文献+

噻托溴胺联合阿奇霉素治疗慢性阻塞性肺疾病 被引量:11

Clinical Significance of Tiotropium with Azithromycin in the Treatment of Chronic Obstructive Pulmonary Disease
下载PDF
导出
摘要 目的:观察噻托溴胺联合阿奇霉素治疗慢性阻塞性肺疾病(COPD)的临床疗效和肺功能变化。方法:选择COPD急性加重期住院患者50例(第1组),COPD稳定期患者42例(第2组),对照组为同期参加呼吸疾病体检的老年人65例。分离外周血单核细胞(PBMC),用直接免疫荧光(DIF)法检测PBMC中的肺炎衣原体(Cpn)特异性抗原(Ag),同时用间接微量免疫荧光(MIF)法检测Cpn抗体(IgA,IgG和IgM)。胶体金法快速定量测定C-反应蛋白(CRP)。结果:第1组Cpn的感染率为66%(33/50),第2组为66.7%(28/42),对照组为21.5%(14/65)。Cpn-Ag和Cpn-IgM抗体的检出率第1组显著高于对照组(P<0.001),Cpn-IgA和IgG抗体的检出率第1组和第2组均显著高于对照组(P<0.01)。治疗后第1组和第2组患者的临床症状均有显著改善:Borg记分下降和FEV1/FVC(%)显著增加(P<0.01);Cpn-IgM阳性率显著下降(P<0.001);第1组和第2组CRP水平下降均有显著差异(P<0.01)。结论:COPD患者有较高的Cpn感染率,噻托溴胺联合阿奇霉素治疗COPD彼此有正协同效应。 Objective:To observe the efficacy and changes in lung function of tiotropium with azithromycin in the treatment of chronic obstructive pulmonary disease(COPD).Methods:The first group consisted of 50 patients who were hospitalized due to acute exacerbation of COPD.The second group consisted of 42 patients with stable COPD.The control group was 65 participants in a community survey of respiratory diseases in the elderly.The human peripheral blood mononuclear cells(PBMC) were separated.The Chlamydia pneumoniae-antigen(Cpn-Ag) was detected by direct immunofluorescence(DIF) method.We measured antibodies against C.pneumoniae using microimmunofluorescence technique(MIF) and rapid quantitation of C-reactive protein(CRP) was measured by DIGFA method.Results:The infection rates of Cpn were 66.0%(33/50) in group one,66.7%(28/42) in group two and 21.5%(14/65) in control,respectively.The prevalences of Cpn-A and Cpn-IgM representing acute infection were significantly higher in group one than in control l(P0.001),the prevalences of Cpn-IgA and Cpn-IgG representing chronic infection were significantly higher in group one and group two than in control(P0.01).After treatment,the patient's clinical symptoms of COPD groups were improved markely.Borg scores were significant less and FEV1/FVC(%) was increased significantly(P0.01).In group one and group two only the positive rate of Cpn-IgM was decreased significantly(P0.001).Falling rate of CRP levels in COPD groups were significant:(P0.01).Conclusions:The patients with COPD have higher Cpn infection rates,tiotropium plus azithromycin for curing COPD have positive synergistic effects with each other.
出处 《中国临床医学》 2011年第3期329-331,共3页 Chinese Journal of Clinical Medicine
关键词 慢性阻塞性肺疾病 噻托溴胺 阿奇霉素 肺炎衣原体 Chronic obstructive pulmonary disease(COPD) Tiotropium Azithromycin Chlamydia pneumoniae(Cpn)
  • 相关文献

参考文献10

  • 1Diederen BM, van der Valk PD, Kluytmans JA, et al. The role of atypical respiratory pathogens in exacerbations of chronic obstructive pulmonary disease [J]. Eur Respir J, 2007,30(2):240-244.
  • 2王卫群,张瑞华,龚辉,余竹元.外周血单核细胞中肺炎衣原体特异性抗原的检测[J].中国临床医学,2002,9(3):243-245. 被引量:15
  • 3Fan P, Dong F, Huang Y, et al. Chlamydia pneumoniae secrection of a proteases-like activity factor for degrading host cell transcription factor required for major histocompatibility complex antigen expres- sion[J]. Infection Immunity, 2002, 70(1):345-349.
  • 4Weis N, Almdal T. C-reactive protein--can it be used as a marker of infection in patients with exacerbation of chronic obstructive pulmo- nary disease? [J]. Eur J Intern Med,2006,17(2) :88-91.
  • 5Brand6n E, Koyi H, Gnarpe J, et al. Intermittent azithromy- cin treatment for respiratory symptoms in patients with chro- nic Chlamydia pneumoniae infection[J]. Scand J Infect Dis, 2004, 36(11-12) :811-816.
  • 6Miyashita N. Chlamydia pneumoniae infections[J]. Kekaku, 2006,81(9) :581-588.
  • 7granden E, Koyi H, Gnarpe J, et al. Chronic Chlamydia pneumoniae infection is a risk factor for the development of COPD[J]. Respir Med, 2005, 99(1) :20-26.
  • 8Mauskopf JA, Baker CL, Monz BU, et al. Cost effectiveness of tiotropium for chronic obstructive pulmonary disease: a systematic review of the evidence[J]. J Med Econ, 2010, 13(3) :403-417.
  • 9林琳,赵立.噻托溴铵联合福莫特罗吸入治疗慢性阻塞性肺疾病[J].实用药物与临床,2009,12(3):184-185. 被引量:8
  • 10Fitch PM, Wheelhouse NM, Bowles P, et al. Eetopic lymph- oid tissue formation in the lungs of mice infected with Chlamydia pneumoniae is associated with epithelial macro- phage inflammatory protein-2/CXCL2 expression [J]. Clin Exp Immunol, 2010, 162(2) : 372-378.

二级参考文献16

  • 1慢性阻塞性肺疾病诊治指南(2007年修订版)[J].中华结核和呼吸杂志,2007,30(1):8-17. 被引量:8234
  • 2Global strategy for the diagnosis,management,and prevention of chronic obstructive pulmonary disease[EB/OL].http://www.goldcopd.com.
  • 3Friedman M,Menjoge SS,Anton SF,et al.Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder(COPD)[J].Pharmacoeconomics,2004,22:741-749.
  • 4Francois Maltais,Alan Hamilton,Darcy Marciniuk,et al.Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD[J].Chest,2005,128:1168-1178.
  • 5陈剑波,陈平.吸入疗法在慢性阻塞性肺疾病治疗中的价值[J].中国实用内科杂志,2007,27(16):1239-1243. 被引量:25
  • 6[1]Heick A, Striver E. Chlamydia penumoniae - associated A DEM. Eur J Neurol, 2000,7(4) :435 ~438.
  • 7[2]Rubegni P, Marano MR, De Aloe G. et al. Sweet's syndrome and Chlamydia pneumoniae infection. J Am Acad Dermatol,2001, 44(5) :862~864.
  • 8[3]Bodetti TJ, Timms P. Detection of Chlamydia pneumoniae DNA and antigen in the circulating mononuclear cell fractions of hu mans and koalas. Infect Immun, 2000, 68(5) :2744~2747.
  • 9[4]Moazed TC, Kuo CC, Grayston JT, et al. Evidence of systemic dissemination of Chlamydia pneumoniae via macrophages in the mouse. J Infec Dis, 1998, 177:1322~1325.
  • 10[5]Muhlestain JB, Hammond EH, Carlquist JF, et al. Increased incidence of chlamydia species with in the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol, 1996; 27: 1555~1561.

共引文献21

同被引文献69

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部